Metraipolis › archive › dc_ddc2780d64da

Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort — Europe PMC PMID:41634843

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41634843
DOI: 10.1186/s13195-[numero omesso]-0
License (as archived): solo-consultazione
Archived: 2026-11-06T03:04:00.119Z
SHA-256 of the archived text: 00fecee3cbc19ec56b13bebcb673dc33c74297a01403c7ffd749bf3d748a504a
Stable URL of this page: https://metraipolis.com/documento/dc_ddc2780d64da

How to cite

Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort — Europe PMC PMID:41634843 — Europe PMC (en), https://europepmc.org/article/MED/41634843 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ddc2780d64da (Metraipolis archive dc_ddc2780d64da, sha256 00fecee3cbc19ec56b13bebcb673dc33c74297a01403c7ffd749bf3d748a504a)

BibTeX

@misc{dcddc2780d64da,
  title = {Are pre-frail and frail amyloid positive individuals eligible to Lecanemab? A cross-sectional analysis from the Cogfrail real-world cohort — Europe PMC PMID:41634843},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41634843},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ddc2780d64da; sha256 00fecee3cbc19ec56b13bebcb673dc33c74297a01403c7ffd749bf3d748a504a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41634843. Agents can read the archived copy with the MCP tool read_document.